๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Belagavi
Clinical trial register · India

Clinical Trials in Belagavi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1132 matching records held by the registry are in this view. Synced 27 Sep 2026, 03:16 UTC
1132
Studies in scope
all four open statuses
613
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
New Delhi 335 Mumbai 261 Hyderabad 238 Bangalore 199 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca24 Novartis Pharmaceuticals8 Bristol-Myers Squibb7 Eli Lilly and Company7 Novo Nordisk A/S4
Site location
New Delhi335 Mumbai261 Hyderabad238 Bangalore199 Pune189
All 275 locations
Target enrolment
to

Trials with a site in Belagavi

94 of 1132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
2,380
Belagavi, Nagpur, Pune, New Delhi, Dehradun, Kolkata, Ahemdabad, Bangalore
2026-12-16
Not yet open
This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis
NCT07840105Complicated Urinary Tract Infections(cUTI), Acute Pyelonephritis
DrugCeftazidime-avibactam
Wockhardt
Phase 2
279
Visakhapatnam, Raipur, Belagavi, Mandya, Mysore, Kozhikode, Nagpur, Nashik
2026-09-30
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
850
Vadodara, Badsa, Gurgaon, Belagavi, Pune, Mohali, Chennai
2026-09-30
Recruiting
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
NCT07624305Renal Insufficiency, Chronic
DrugsBalcinrenone/dapagliflozin·Dapagliflozin
AstraZeneca
Phase 3
2,800
Aligarh, Belagavi, Bhubaneswar, Calicut, Coimbatore, Dehli, Dehradun, Hyderabad
2026-09-01
Not yet open
Breastfeeding Education Support Tool
NCT06797063Breastfeeding, Exclusive, Infant Development, Infant Growth, Breast Feeding
Thomas Jefferson University
Not applicable
336
Belagavi
2026-09-01
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Belagavi, Calicut, Coimbatore, Dehradun, Delhi, Hyderabad, Jaipur, Kanpur
2026-08-24
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
7,000
Aligarh, Bangalore, Belagavi, Bhubaneswar, Calicut, Chennai, Dehradun, Delhi
2026-08-21
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
DrugElecoglipron
AstraZeneca
Phase 3
600
Bangalore, Belagavi, Chennai, Coimbatore, Guntur, Hyderabad, Indore, Kochi
2026-07-08
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
900
Aligarh, Belagavi, Belgavi, Calicut, Chennai, Coimbatore, Delhi, Guntur
2026-07-06
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109Type 2 Diabetes Mellitus
DrugsElecoglipron·Dapagliflozin
AstraZeneca
Phase 3
2,000
Bangalore, Belagavi, Calicut, Chennai, Coimbatore, Guwahati, Indore, Jaipur
2026-07-06
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
DrugElecoglipron
AstraZeneca
Phase 3
4,500
Bangalore, Belagavi, Bikaner, Delhi, Guntur, Hyderabad, Jaipur, Jodhpur
2026-06-29
Recruiting
A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
NCT07653100Respiratory Syncytial Virus (RSV)
DrugRSVpreF
Pfizer
Phase 3
540
Visakhapatnam, Bangalore, Belagavi, Nashik, Pune, Dwarka, New Delhi, Jaipur
2026-06-22
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450Acute Ischemic Stroke
DrugTAK-755
Takeda
Phase 2
222
Belagavi, Kochi, Ludhiana, Kolkata, New Delhi
2026-05-17
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
5,700
Guntur, Ahmedabad, Vadodara, Belagavi, Mangalore, Manipal, Kochi, Nagpur
2026-05-11
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
5,610
Guntur, Vijayawada, Raipur, Vadodara, Gurgaon, Gurugram, Bangalore, Belagavi
2026-05-11
Recruiting
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
NCT07606066Type 2 Diabetes
AstraZeneca
Observational
2,150
Guntur, Guwahati, Bangalore, Belagavi, Calicut, Kochi, Thiruvananthapuram, Indore
2026-05-06
Recruiting
Caffeine for Hypoxic Ischemic Encephalopathy
NCT06855108Hypoxic Ischemic Encephalopathy (HIE)
NICHD Global Network for Women's and Children's Health
Phase 3
830
Belagavi, Nagpur
2026-04-08
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Allahฤbฤd, Belagavi, Belgavi, Hyderabad, Jaipur, Kochi, Lucknow, Mumbai
2026-03-26
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177Non-segmental Vitiligo
DrugGIA632
Novartis Pharmaceuticals
Phase 2
210
Ahmedabad, Bangalore, Belagavi, Mysore, Nashik
2026-03-09
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302Acute Ischemic Stroke
DrugTenecteplase
Boehringer Ingelheim
Phase 3
1,325
Ahmedabad, Bangalore, Belagavi, Bhubaneswar, Bikaner, Calicut, Chandigarh, Coimbatore
2026-02-17
Recruiting
Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage
NCT07243704Intracerebral Haemorrhage
DrugAspirin
Christian Medical College and Hospital, Ludhiana, India
Phase 3
5,676
Guntur, Kฤkinฤda, Nellore, Guwahati, Tezpur, Patna, Ranchi, Belagavi
2026-02-16
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694Moderate to Severe Chronic Obstructive Pulmonary Disease
Pfizer
Phase 2/3
1,156
Belagavi, Thane, New Delhi, Ajmer, Jaipur, Coimbatore, Hyderabad, Dehradun
2026-02-11
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703Cervical Cancer
DrugsSacituzumab tirumotecan·Bevacizumab·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
1,023
Visakhapatnam, Belagavi
2026-01-19
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Surat, Vadodara, Gurugram, Bangalore, Belagavi, Kottayam, Nagpur, Nashik
2026-01-06
Recruiting
Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries
NCT06723392Preterm Birth, Small for Gestational Age (SGA), Stillbirth, Bacteriuria (Asymptomatic) in Pregnancy
NICHD Global Network for Women's and Children's Health
Phase 3
1,134
Belagavi, Nagpur
2025-12-08
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
7,140
Ahmedabad, Bangalore, Belagavi, Bhubaneswar, Guntur, Hubli, Hyderabad, Kanpur
2025-12-01
Recruiting
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
NCT07102628Acute Coronary Syndrome
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
300
Belagavi, Mumbai, Nashik, Bikaner
2025-10-03
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,000
Ahmedabad, Belagavi, Belgavi, Bhubaneswar, Chandigarh, Chennai, Hyderabad, Nagpur
2025-09-30
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
DrugZilebesiran
Alnylam Pharmaceuticals
Phase 3
11,000
Ahmedabad, Belagavi, Bhฤratnagar, Chhatrapati Sambhajinagar, Coimbatore, Dehradun, Guntur, Hyderabad
2025-09-22
Active, closed
A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
NCT07004972Symptomatic Obstructive Hypertrophic Cardiomyopathy
DrugMavacamten
Bristol-Myers Squibb
Phase 4
50
Hyderabad, Ahmedabad, Surat, Gurgaon, Belagavi, Mangalore, Ernฤkulam, Kottayam
2025-09-04
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Belagavi, Belgavi, Jaipur, Kanpur, Kozhikode, Lucknow, Nagpur, Nashik
2025-09-02
Recruiting
A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India
NCT07157423Severe Postpartum Haemorrhage
DrugRecombinant Factor VIIa
Novo Nordisk A/S
Phase 4
64
Belagavi, Mysore, Kozhikode, Mumbai, New Delhi, Jaipur, Udaipur, Hyderabad
2025-08-26
Recruiting
Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy
NCT07669519Fatigue, Colon Cancer
Natureceuticals Sdn Bhd
Phase 3
180
Srikakulam, Belagavi, Mysuru, Satara, Talegaon Dฤbhฤde, Lucknow
2025-08-18
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
DrugBaxdrostat
AstraZeneca
Phase 3
250
Belagavi, Delhi, Hyderabad, Kolkata, Mumbai
2025-08-07
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273Bipolar Disorder Type I With Mania
DrugsValproate·Lamotrigine·Lithium·KarXT
Bristol-Myers Squibb
Phase 3
450
Vadodara, Belagavi, Mangalore, Kozhikode, Ludhiana, Madurai, Hyderabad, Kolkata
2025-07-18
Recruiting
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 2
987
Belagavi, Coimbatore, Dehradun, Delhi, Dwฤrka, Hyderabad, Kochi, Mumbai
2025-06-27
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features
DrugKarXT
Bristol-Myers Squibb
Phase 3
274
Vadodara, Belagavi, Kozhikode, Ludhiana, Hyderabad, Kolkata
2025-06-13
Recruiting
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
NCT07000357Cardiovascular Disease
DrugAZD0780
AstraZeneca
Phase 3
15,100
Ahmedabad, Aurangabad, Bangalore, Belagavi, Bikaner, Calicut, Chennai, Coimbatore
2025-06-04
Active, closed
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT07037277HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
DrugsBemnifosbuvir-Ruzasvir·Sofosbuvir-Velpatasvir
Atea Pharmaceuticals, Inc.
Phase 3
880
Hyderabad, Patna, Rajkot, Surat, Shimla, Belagavi, Kochi, Mumbai
2025-06-02
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123Cardiovascular Disease
DrugAZD0780
AstraZeneca
Phase 3
3,103
Belagavi, Dehradun, Kanpur, Kochi, New Delhi
2025-05-28
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
DrugTozorakimab
AstraZeneca
Phase 2
540
Belagavi, Coimbatore, Dehradun, Delhi, Faridabad, Gurgaon, Kochi, Lucknow
2025-03-26
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
DrugTezepelumab
AstraZeneca
Phase 3
990
Ahmedabad, Aligarh, Belagavi, Coimbatore, Dehradun, Delhi, Dwฤrka, Faridabad
2025-03-18
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Ahmedabad, Ajmer, Bangalore, Belagavi, Dehradun, Delhi, Gurgaon, Hyderabad
2025-03-14
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
5,000
Bangalore, Belagavi, Hyderabad, Kolkata, Madurai, Mumbai, New Delhi, Pune
2025-03-03
Recruiting
LIFT-UP: Randomized Controlled Trial of Fortification of Human Milk
NCT06765863Very Preterm Infant, Very Low Birthweight
Harvard School of Public Health (HSPH)
Not applicable
776
Ballary, Belagavi, Davangere, Hyderabad
2025-01-16
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin
Jazz Pharmaceuticals
Phase 3
286
Belagavi, Mumbai, Nashik, Hyderabad, Varanasi, New Delhi
2024-07-19
Recruiting
Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries- PreTerm
NCT06240715Preterm, Infant Death
Nemours Children's Clinic
Not applicable
800
Belagavi, Chandrapur, Nagpur, Pune, Wardha, Jaipur, Hyderabad
2024-07-01
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone
Celgene
Phase 3
850
Belagavi, Kochi, Mumbai, New Delhi, Howrah, New Town
2024-06-19
Active, closed
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076Lung Cancer, Non-Small Cell
DrugsBelrestotug·Dostarlimab·Pembrolizumab
GlaxoSmithKline
Phase 3
88
Gokul Shirgoan, Apex Wellness Hospital, Bangalore, Belagavi, Bhubaneswar, Gurgaon, New Delhi
2024-06-10
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Ahmedabad, Belagavi, Chandigarh, Faridabad, Kolkata, Nagpur, Pune
2024-05-08
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
Ahmedabad, Ajmer, Amritsar, Bangalore, Belagavi, Coimbatore, Dehradun, Delhi
2024-04-12
Active, closed
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207Heart Failure, Systemic Inflammation
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
680
Vijayawada, Visakhapatnam, Vadodara, Belagavi, Bengaluru, Mysuru, Udupi, Nagpur
2024-04-01
Active, closed
Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)
NCT05983471Idiopathic Pulmonary Fibrosis, Cough, IPF, Fibrotic Lung Disease
Melius Pharma AB
Phase 2
40
Guntur, Belagavi, Pune, Coimbatore, Kanpur, Kolkata
2024-04-01
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
2,554
Bangalore, Belagavi, Calicut, Chennai, Coimbatore, Dehradun, Hyderabad, Kolkata
2024-03-29
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Belagavi, Bikaner, Dehradun, Kanpur, Kochi, Kozhikode, Lucknow, Nashik
2024-03-05
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966COPD (Chronic Obstructive Pulmonary Disease)
AstraZeneca
Phase 3
5,000
Ahmedabad, Aligarh, Belagavi, Calicut, Chandigarh, Dehradun, Delhi, Dwฤrka
2024-02-21
Recruiting
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
NCT06006559Dengue
Novartis Pharmaceuticals
Phase 2
108
Belagavi, Mumbai, Pune, Jaipur, Chennai
2024-02-20
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
1,264
Ahmedabad, Belagavi, Bengaluru, Bhubaneswar, Coimbatore, Hyderabad, Karad, Kolhฤpur
2023-12-21
Active, closed
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478Chronic Spontaneous Urticaria
DrugsOmalizumab·Remibrutinib
Novartis Pharmaceuticals
Phase 3
470
Ahmedabad, Bangalore, Belagavi, Mysore, Nagpur, Nashik, New Delhi, Bikaner
2023-11-15
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
DrugDapagliflozin
AstraZeneca
Phase 3
1,835
Bangalore, Belagavi, Delhi, Nadiฤd, New Delhi
2023-11-07
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Ahmedabad, Surat, Belagavi, Bhopal, Nagpur, Pune, New Delhi, Mohali
2023-10-25
Recruiting
A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)
NCT05984147Relapsed Advanced Lymphomas
Aurigene Discovery Technologies Limited
Phase 1
40
Visakhapatnam, Chandigarh, Ahmedabad, Surat, Rohtak, Srinagar, Belagavi, Kochi
2023-10-19
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,255
Ahmedabad, Surat, Belagavi, Bhopal, Nagpur, Pune, New Delhi, Mohali
2023-09-14
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
DrugsCapeox·Dostarlimab·Folfox
GlaxoSmithKline
Phase 3
892
Bengaluru, Ludhiana, Belagavi, Hyderabad, Nashik, Pune
2023-08-01
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
DrugsMilvexian·Apixaban
Janssen Research & Development, LLC
Phase 3
20,284
Aligarh, Amritsar, Aurangabad, Bangalore, Belagavi, Bengaluru, Bikaner, Chennai
2023-04-11
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
4,300
Bangalore, Belagavi, Bhubaneswar, Hubli, Hyderabad, Jaipur, Kolkata, Mumbai
2023-03-31
Recruiting
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
NCT05696613Primary Membranous Nephropathy
DrugRituximab
Cerium Pharmaceuticals, Inc.
Phase 3
148
Guntur, Nellore, Raipur, Nadiฤd, Belagavi, Nagpur, New Delhi, Chandigarh
2023-03-13
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Guntur, Ahmedabad, Bangalore, Belagavi, Mangalore, Manipal, Mysore, Kochi
2023-03-09
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Ahmedabad, Ajmer, Anand, Bangalore, Belagavi, Bhubaneswar, Bikaner, Chennai
2023-02-15
Active, closed
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
NCT05605535Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma
DrugsOregovomab·Paclitaxel·Carboplatin
CanariaBio Inc.
Phase 2
88
Visakhapatnam, Vadodara, Belagavi, Kochi, Trivandrum, Puducherry, Jaipur, Chennai
2023-02-07
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
DrugTozorakimab
AstraZeneca
Phase 3
3,527
Ahmedabad, Belagavi, Chennai, Dehradun, Gurgaon, Gurugram, Hyderabad, Kanpur
2022-12-13
Active, closed
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001Chronic Spontaneous Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
696
Belagavi
2022-12-09
Active, closed
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05600777Cough, Refractory Chronic Cough
DrugBLU-5937
Bellus Health Inc. - a GSK company
Phase 3
997
Belagavi, Faridabad, Nagpur, Nashik, Visakhapatnam
2022-12-05
Active, closed
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
3,400
Surat, Belagavi, Kozhikode, Mumbai, Nagpur, Pune, Delhi, Chandigarh
2022-11-01
Active, closed
Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries
NCT03657394Hypoxic-Ischemic Encephalopathy, Birth Asphyxia
Nemours Children's Clinic
Not applicable
3,442
Belagavi, Nagpur, Pune, Chandrapur, Wardha, Jaipur
2022-10-17
Active, closed
Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries Developmental Follow Up
NCT03682042Hypoxic-Ischemic Encephalopathy, Birth Asphyxia
Nemours Children's Clinic
Not applicable
3,442
Belagavi, Nagpur, Pune, Chandrapur, Wardha, Jaipur
2022-10-17
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Ahmedabad, Bangalore, Belagavi, Bhubaneswar, Chandigarh, Chennai, Hyderabad, Kanpur
2022-10-04
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Pomalidomide·Bortezomib·Dexamethasone
Celgene
Phase 3
810
Ahmedabad, Gurugram, Belagavi, Mumbai, Madurai, Varanasi, Ludhiana, Puducherry
2022-09-20
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 2/3
1,856
Ahmedabad, Belagavi, Chandigarh, Kolkata, Nagpur, Pune
2022-08-22
Recruiting
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
NCT05348876Non-metastatic Castration-resistant Prostate Cancer
DrugDarolutamide
Bayer
Phase 4
50
Vijayawada, Visakhapatnam, Nadiฤd, Surat, Belagavi, Bengaluru, Kochi, Thiruvananthapuram
2022-08-03
Active, closed
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
NCT05297448Hepatic Encephalopathy
DrugRifaximin SSD
Bausch Health Americas, Inc.
Phase 3
466
Belagavi, Mangaluru, Nagpur, Nashik, Secunderabad, Sลซrat
2022-08-03
Active, closed
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116Psoriatic Arthritis
Sun Pharmaceutical Industries Limited
Phase 3
529
Surat, Belagavi, Hubli, Pune, Bangalore, Chennai, Secunderabad, Sevilla
2022-06-30
Active, closed
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859Hepatitis B
DrugBepirovirsen
GlaxoSmithKline
Phase 2
360
Belagavi, Coimbatore, Hyderabad, Kanchan Bagh Hyderabad, Mumbai, New Delhi, Pune, Surat
2021-12-14
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
DrugInclisiran sodium
Novartis Pharmaceuticals
Phase 3
17,004
Guntur, Hyderabad, Ahmedabad, Vadodara, Belagavi, Manipal, Mysore, Kochi
2021-11-23
Active, closed
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090Papillary Renal Cell Carcinoma
DrugsSavolitinib·Sunitinib·Durvalumab
AstraZeneca
Phase 3
148
Bangalore, Belagavi, Jaipur, Mysore, Nashik
2021-10-28
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
DrugGiredestrant
Hoffmann-La Roche
Phase 3
4,170
Vijayawada, Patna, Ahmedabad, Surat, Vadodara, Belagavi, Amravati, Kolhฤpur
2021-08-27
By invitation
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
NCT04957719Acute Myocardial Infarction
Viatris Innovation GmbH
Phase 3
25,000
Ahmedabad, Aligarh, Aurangabad, Bangalore, Bathinda, Belagavi, Bhubaneswar, Bikaner
2021-08-14
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsAdagrasib·Pembrolizumab
Mirati Therapeutics Inc.
Phase 2/3
626
Ahemdabad, Ahmedabad, Aurangabad, Bangalore, Belagavi, Howrah, Hyderabad, Jaipur
2020-12-02
Recruiting
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
NCT04462770Dravet Syndrome
DrugClemizole HCl
Epygenix
Phase 3
150
Hyderabad, Surat, Belagavi, Bengaluru, Kochi, Pune, Mumbai, Nagpur
2020-09-15
Active, closed
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naรฏve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
NCT04314531Active Psoriatic Arthritis
Sun Pharmaceutical Industries Limited
Phase 3
296
Surat, Bangalore, Belagavi, Hubli, Pune, Hyderabad, Lucknow, Kochi
2020-07-01
Active, closed
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486Non-Small Cell Lung Cancer
DrugsPemetrexed/Cisplatin·Pemetrexed/Carboplatin·Osimertinib
AstraZeneca
Phase 3
587
Belagavi, Bengaluru, Gurgaon, Kolkata, New Delhi, Pune
2019-07-02
Recruiting
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
NCT03633708Secondary Hyperparathyroidism, Chronic Kidney Disease
DrugEtelcalcetide
Amgen
Phase 3
56
Bangalore, Belagavi, New Delhi, Kolkata
2019-04-29
Recruiting
PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
NCT04054414Acute Spinal Cord Injury
Pharmazz, Inc.
Phase 2
40
Belagavi, Kolkata, Lucknow, Nagpur, New Delhi
2019-01-10
Recruiting
Maternal Newborn Health Registry
NCT01073475Pregnancy Outcome Trends in Low-resource Geographic Areas
NICHD Global Network for Women's and Children's Health
Observational
950,000
Nagpur, Belagavi
2008-05
Rows per page Showing 1–94 of 94
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-india/city/belagavi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in India and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,132 studies in total at the last sync on 27 Sep 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 94 of those studies with a site in Belagavi.

How many clinical trials are recruiting in Belagavi?

56 of the 94 studies on this page are recruiting new participants as of the 27 Sep 2026, 03:16 UTC sync. A further 4 have not yet opened recruitment, 33 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Belagavi), 94 studies
PhaseStudiesRecruitingShare
Phase 3694073.4%
Phase 211711.7%
Not applicable525.3%
Phase 2/3323.2%
Phase 4323.2%
Observational222.1%
Phase 1111.1%

Most active sponsors

Lead sponsors with the most studies (Belagavi)
Lead sponsorStudiesRecruiting
AstraZeneca2419
Novartis Pharmaceuticals84
Bristol-Myers Squibb72
Eli Lilly and Company75
Novo Nordisk A/S42
GlaxoSmithKline31
Nemours Children's Clinic31
NICHD Global Network for Women's and Children's Health33
Pfizer33
Celgene21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.